DrugPatentWatch Database Preview

Teva Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?

TEVA has seven hundred and twenty-two approved drugs.

There are seventy-three US patents protecting TEVA drugs. There are forty-three tentative approvals on TEVA drugs.

There are eight hundred patent family members on TEVA drugs in forty-six countries and five hundred and fifty-four supplementary protection certificates in fourteen countries.

Summary for Teva

International Patents:	800
US Patents:	73
Tradenames:	480
Ingredients:	419
NDAs:	722
Patent Litigation for Teva:	See patent lawsuits for Teva
PTAB Cases with Teva as petitioner:	See PTAB cases with Teva as petitioner

Drugs and US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	ENALAPRIL MALEATE	enalapril maleate	TABLET;ORAL	075479-001	Aug 22, 2000	AB	RX	No	No
Teva Pharms Usa	DEXMETHYLPHENIDATE HYDROCHLORIDE	dexmethylphenidate hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	202731-001	Jul 5, 2017	AB	RX	No	No
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-001	Jan 27, 2017		RX	Yes	No	8,651,103		Y

Expired US Patents for Teva

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	QNASL	beclomethasone dipropionate	AEROSOL, METERED;NASAL	202813-002	Dec 17, 2014	5,776,432
Teva Womens	PREFEST	estradiol; norgestimate	TABLET;ORAL	021040-001	Oct 22, 1999	5,108,995
Teva Branded Pharm	SEASONALE	ethinyl estradiol; levonorgestrel	TABLET;ORAL	021544-001	Sep 5, 2003	RE39861

Paragraph IV (Patent) Challenges for TEVA drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	1.25 mg		2008-11-03
	Tablets	0.3 mg, 0.45 mg and 0.9 mg		2009-03-19
	Tablets	0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg		2013-07-10
	Tablets	0.15 mg/0.03 mg/0.01 mg		2008-01-22
	for Injection	3.5 mg/vial		2016-10-26
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Tablets	5 mg, 10 mg, 20 mg, 30 mg		2009-11-18
	Tablets	0.5 mg and 1 mg		2010-05-17
	Tablets	0.625 mg		2009-03-02
	Tablets	0.1 mg/0.02 mg and 0.01 mg		2009-11-16
	Tablets	0.15 mg/0.03 mg		2004-03-29
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Delayed-release Tablets	20 mg		2015-06-03
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26

Premature patent expirations for TEVA

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

International Patents for Teva Drugs

Country	Document Number	Estimated Expiration
European Patent Office	2326643
Brazil	PI0608209
Japan	2011517654

Supplementary Protection Certificates for Teva Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C/GB01/025	United Kingdom		PRODUCT NAME: LINEZOLID; REGISTERED: UK PL 00032/0259 20010105; UK PL 00032/0260 20010105; UK PL 00032/0261 20010105; UK PL 00032/0262 20010105
C0036	France		PRODUCT NAME: COMBINAISON DE RILPIVIRINE ET TOUTES SES FORMES THERAPEUTIQUEMENT EQUIVALENTES PROTEGEES PAR LE BREVET DE BASE, TELLES QUE LES SELS D'ADDITION PHARMACEUTIQUEMENT ACCEPTABLES DE RILPIVIRINE, Y COMPRIS LE SEL D'ACIDE CHLORHYDRIQUE DE RILPIVIRINE ET DE TENOFOVIR, EN PARTICULIER LE TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/11/737/001 20111128
C/GB99/046	United Kingdom		PRODUCT NAME: EPTIFIBATIDE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: CH 54054 19970227; CH 54050 19970227; UK EU/1/99/109/001 19990701; UK EU/1/99/109/002 19990701

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral